Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who voluntarily signed the informed consent to participate in this study.~* Adults aged 19-75 years.~* Those diagnosed with type 2 diabetes mellitus.~* 7% ≤ HbA1c ≤ 10.5%~* FPG ≤ 270 mg/dL~* BMI ≤ 40 kg/㎡~* Subjects able to understand the study, comply with study procedures, and attend all scheduled visits.~Exclusion Criteria:~* Those who suffered from acute or chronic metabolic acidosis, lactic acidosis and diabetic ketoacidosis.~* Those who had genetic disorders such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption.~* Those with heart failure (NYHA class II\~IV) or who had suffered from heart failure.~* Those with a history of malignant tumor within 5 years~* Those who have a clinically significant liver disease~* Those who have a clinically significant renal disease~* SBP \> 180 mmHg or DBP \> 110 mmHg~* Those who had allergic reaction to main ingredients or components of the investigational products.~* Patients planning to become pregnant or of childbearing potential, but not using any recognized contraceptive method~* Females who are pregnant or breastfeeding.~* AST or ALT ≥ LRN\*3~* TG ≥ 500 mg/dL

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AJU-A51+A51R2 placebo+A51R3 (Type: EXPERIMENTAL): None
- AJU-A51 placebo+A51R2+A51R3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).